N2OFF
Computational biotech platform with solar and post-harvest agriculture assets.
Something off on this page? Send us feedback.
Profile
Nexentis Technologies, formerly N2OFF, is a Nasdaq-listed company centered on MitoCareX Bio, a mitochondrial SLC25 drug discovery platform. It also manages European renewable-energy investments and a Save Foods subsidiary focused on post-harvest produce treatment.
Nexentis Technologies emerged from N2OFF's February 2026 rebranding after the company acquired MitoCareX Bio in October 2025 and made it a wholly owned subsidiary. Its core business is now computational drug discovery around mitochondrial SLC25 carrier proteins, using MitoCareX's MITOLINE platform for structural modeling, virtual screening, and early biological validation of small-molecule candidates in resistant cancer and inflammatory metabolic disease programs.
The company still manages a portfolio outside biotech: European solar projects under a Ready to Build investment model and a Save Foods subsidiary that develops post-harvest treatments for fruits and vegetables. The business is early-stage and depends on preclinical progress, access to capital, partner interest, and management's ability to balance biotech development with non-core energy and agriculture assets.
Company facts
Key statistics
Year to date −72.5% · Average volume (30d) 89.9K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| May 14, 2026Q1 FY26 | — | −$10.74 | — | — | — | — | −3.88% |
| Mar 31, 2026Q4 FY25 | — | $4.99 | — | — | −$68.0K | — | −0.43% |
| Nov 13, 2025Q3 FY25 | — | −$8.29 | — | — | $2.0K | — | −2.87% |
| Aug 14, 2025Q2 FY25 | — | −$6.29 | — | — | — | — | −0.65% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $66.0K | $0 | $2.0K | −$68.0K | $0 | $0 | |
| Gross profit | $52.0K | −$2.0K | −$3.0K | −$126.0K | −$103.0K | $0 | |
| Operating income | −$619.0K | −$2.8M | −$1.2M | −$396.0K | −$2.2M | $0 | |
| Net income | −$1.2M | −$4.5M | $429.0K | $1.3M | −$7.5M | $0 | |
| Diluted EPS | −$2.58 | −$0.18 | $0.45 | −$1.26 | −$10.74 | $0.00 | |
| Gross margin | 78.8% | — | -150.0% | — | — | — | |
| Operating margin | -937.9% | — | -59,100.0% | — | — | — |
Fiscal years (4-quarter sums)FY22 $394.0K · FY23 $263.4K · FY24 $210.6K · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $8.9M · Total debt $219.0K · Total assets $13.2M · Shareholders' equity $12.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 953.0K · Float 570.0K
Insiders — no current Form 4 position.
This issuer lists more than one class and the share count spans them all, so a stake here reads as a share of the whole company, not of this class.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % of company | Form | Filed |
|---|---|---|---|---|
| SciSparc Ltd. · 10 percent owner | 490.8K | Form 4 | Oct 24, 2025 | |
| Silberman Alon · 10 percent owner | 454.1K | Form 4 | Oct 28, 2025 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
Not reported.